Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Apr 14, 2022
Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Apr 12, 2022
Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual Meeting Apr 11, 2022
Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting Mar 15, 2022
Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update Feb 11, 2022
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells Feb 3, 2022
Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma Jan 12, 2022
